Fuming Zi
Nanchang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions.
Journal: International immunopharmacology
Published: February 24, 2026
Clostridium butyricum alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K/AKT pathway through the gut‒bone axis.
Journal: Gut microbes
Published: January 02, 2026
lncRNA H19 plays a role in multiple myeloma via interacting with hnRNPA2B1 to stabilize BET proteins by targeting osteoclasts and osteoblasts.
Journal: International immunopharmacology
Published: May 16, 2024
A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors.
Journal: Frontiers in oncology
Published: September 20, 2022
Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis.
Journal: International immunopharmacology
Published: July 23, 2022
A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors.
Journal: Scientific reports
Published: March 26, 2022
A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
Journal: Cellular immunology
Published: December 17, 2020
Expression and role of fibroblast activation protein α in acute myeloid leukemia.
Journal: Oncology reports
Published: July 12, 2020
Ibrutinib in CLL/SLL: From bench to bedside (Review).
Journal: Oncology reports
Published: December 18, 2018
Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells.
Journal: Oncotarget
Published: March 14, 2017
I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages.
Journal: Molecular medicine reports
Published: November 10, 2016
Last Updated: 09/26/2026